Press Releases and Media Coverage

2019-11/26
United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421
1
2019-11/08
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria
2
2019-10/23
In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval
3
2019-10/07
PharmaBoardRoom interview of Dr. Chang Yi Wang, Chairperson and Chief Scientific Officer of United Biopharma (UBP)
4
2019-09/25
UBI Asia announces IND acceptance by TFDA to conduct the first-in-human (FIH) phase-I trial in adults allergic rhinitis patients for UB-211, an UBITh® Allergy Immunotherapeutic Vaccine
5
2019-07/20
A vaccine for Alzheimer’s is on the verge of becoming a reality
6
2019-06/06
Is an Alzheimer’s Cure on the Horizon?
7
2019-06/11
United BioPharma Receives US FDA Approval for UB-621 Phase 2 Trial in Recurrent Genital Herpes Patients
8
2019-05/21
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection
9
2019-11/26
United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421
1
2019-11/08
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria
2
2019-10/23
In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval
3
2019-10/07
PharmaBoardRoom interview of Dr. Chang Yi Wang, Chairperson and Chief Scientific Officer of United Biopharma (UBP)
4
2019-09/25
UBI Asia announces IND acceptance by TFDA to conduct the first-in-human (FIH) phase-I trial in adults allergic rhinitis patients for UB-211, an UBITh® Allergy Immunotherapeutic Vaccine
5
2019-07/20
A vaccine for Alzheimer’s is on the verge of becoming a reality
6
2019-06/06
Is an Alzheimer’s Cure on the Horizon?
7
2019-06/11
United BioPharma Receives US FDA Approval for UB-621 Phase 2 Trial in Recurrent Genital Herpes Patients
8
2019-05/21
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection
9